Abstract:Introduction: To identify the absolute risk of specific HPV genotype for cervical intraepithelial neoplasia grade 2/3 or worse (CIN2/3+) and form the risk-based management strategy by extended HPV genotyping in HPV positive population.Methods: HPV genotyping was performed based on 3-years cervical cancer screening cohort including 10314 women from 2 clinical trials. The study endpoints were histological CIN2+/3+. The prevalence of specific HPV genotype was calculated by minimum estimate, any type estimate and hierarchical attribution estimate. The absolute CIN2+/3+ risks of specific HPV genotype, cytology and combined test were estimated and risk-based management strategy was established according to ASCCP guideline. The performance of conventional and risk-based management strategies for non-16/18 HPVs to detect CIN2+/3+ were further evaluated.Findings: Eligible data were available for 8370 women with median age of 48 (IQR 42-53). At baseline, HPV positive women were 1062, including 424 multiple infections and 639 single infections. CIN2+/3+ cases were 113/74, 23/8, 20/7 and 52/31 at baseline, the 1st, 2nd and 3rd year of visit. Women with multiple HPV infections at baseline were prone to persistent infection than single infection (p<0.0001). HPV16 and 52 were top two ranking among baseline and 3-years cumulative CIN2+/3+ cases. Based on the absolute risk of specific HPV genotype combined with cytology for CIN2+/3+, all non-16/18 HPVs were divided into 4 risk stratified groups. Compared to conventional strategy, the risk-based strategies had higher specificity (p=0.0000) and PPV (p=0.0322) to detect CIN3+, and needed fewer colposcopies for each CIN3+ case.Interpretation: We proposed a new extended HPV genotyping protocol based on the absolute risk of specific HPV genotype, and corresponding management thresholds were suggested for achieving the precise risk-based management of HPV positive population.Funding Information: Supported by the key research and development program of Zhejiang province, China (Grant No: 2020C03025).Declaration of Interests: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare.Ethics Approval Statement: The study was approved by the Ethics Committee of Women’s Hospital, Zhejiang University School of Medicine (IRB-20200240-R). Informed consent was obtained for clinical trial.

Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

Nationwide registry-based trial of risk-stratified cervical screening

The Swedish Cervical Screening Cohort

Extended Human Papilloma Virus Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2 or Worse in a Cohort Study

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system

Diagnostic accuracy of extended HPV DNA genotyping and its application for risk-based cervical cancer screening strategy

Performance of human papillomavirus (HPV) mRNA testing and HPV 16 and 18/45 genotyping combined with age stratification in the triaging of women with ASC-US cytology

Human papillomavirus genotype distribution in cytologically screened women from northwest Germany

Characterization of High-Risk-Other Human Papillomavirus Genotypes in Papanicolaou Tests, High-Grade Squamous Intraepithelial Lesions, and Cervical Cancer

The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: A retrospective study of 8726 cases

Divergent effects of switching from cytology to HPV-based screening in the Nordic countries

Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine

Genotyping of Human Papillomavirus in Cervical Lesions by L1 Consensus PCR and the Luminex Xmap System.

Retrospective analysis of HPV infection: Cotesting and HPV genotyping in cervical cancer screening within a large academic health care system

A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ.

Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study

The role of human papillomavirus genotyping for detecting high-grade intraepithelial neoplasia or cancer in HPV-positive women with normal cytology: a study from a hospital in northeastern China

Cervical cancer prevention among long-term screening non-attendees by vaginal self-collected samples for hr-HPV mRNA detection